Navigation Links
Watson Confirms BYSTOLIC(R) Patent Challenge
Date:3/14/2012

PARSIPPANY, N.J., March 14, 2012 /PRNewswire/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today confirmed that its subsidiary, Watson Laboratories, Inc., filed an Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) seeking approval to market Nebivolol Hydrochloride Tablets, 2.5 mg, 5 mg, 10 mg and 20 mg. Watson's ANDA product is a generic version of Forest Laboratories' BYSTOLIC®, which is a beta-adrenergic blocking agent that is approved for the treatment of hypertension.

Forest Laboratories filed suit against Watson on March 13, 2012, in the United States District Court for the District of Delaware seeking to prevent Watson from commercializing its product prior to the expiration of U.S. Patent No. 6,545,040.  The lawsuit was filed under the provisions of the Hatch-Waxman Act, resulting in a stay of final FDA approval of Watson's ANDA until June 17, 2015 or final resolution of the matter before the court, whichever occurs sooner, subject to any other exclusivities.

Based on available information, Watson believes it may be a "first applicant" to file an ANDA for the generic version of BYSTOLIC® and, should its ANDA be approved, may be entitled to 180 days of generic market exclusivity.

For the twelve months ending January 31, 2012, BYSTOLIC® had total U.S. sales of approximately $391 million according to IMS Health data.

About Watson Pharmaceuticals, Inc.Watson Pharmaceuticals, Inc. is a leading integrated global pharmaceutical company. The Company is engaged in the development and distribution of generic pharmaceuticals and specialized branded pharmaceutical products focused on Urology and Women's Health. Watson has operations in many of the world's established and growing international markets.

For press release and other company information, visit Watson Pharmaceuticals' Web site at http://www.watson.com.

Forward-Looking Statement Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect Watson's current perspective of existing information as of the date of this release. It is important to note that Watson's goals and expectations are not predictions of actual performance. Actual results may differ materially from Watson's current expectations depending upon a number of factors, risks and uncertainties affecting Watson's business. These factors include, among others, the difficulty of predicting the timing or outcome of product development efforts, including FDA and other regulatory agency approvals and actions, if any; the difficulty of predicting the timing and outcome of the pending patent litigation; the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to Watson and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in Watson's periodic public filings with the Securities and Exchange Commission, including but not limited to Watson's annual report on Form 10-K for the year ended December 31, 2011. Except as expressly required by law, Watson disclaims any intent or obligation to update these forward-looking statements.

BYSTOLIC® is a registered trademark of Forest Laboratories, Inc.  

(Logo: http://photos.prnewswire.com/prnh/20100121/LA41294LOGO)CONTACTS:Investors: 

Patty Eisenhaur  

(862) 261-8141 

  

Media: 

Charlie Mayr 

(862) 261-8030


'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Watson Launches Generic PROMETRIUM(R)
2. Watson to Present at the Barclays Capital 2012 Global Healthcare Conference
3. Watson Receives Complete Response Letter from FDA for Progesterone Vaginal Gel 8%
4. Watson to Present at the 2012 RBC Capital Markets Healthcare Conference
5. Watson to Present at the Citi 2012 Global Healthcare Conference
6. Watson Full Year 2011 Net Revenue Increases 29% to $4.58 Billion;
7. Watson Provides Update on Generic Lidoderm® Application
8. Watson Reaches Settlement with Mallinckrodt Over Exalgo(R)
9. Watson Confirms Court Stays Preliminary Injunction
10. Watson Announces Preliminary 2011 Non-GAAP Earnings of $4.75-$4.77
11. Watson Acquires Ascent Pharmahealth for AU$375 Million
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... -- Elekta today announced that its leading-edge ... focal point of seven scientific presentations at ESTRO 35, ... & Oncology, taking place April 29 - May 3. ... and a high-field MRI scanner with sophisticated software that ... in real time. The MR-linac is designed to improve ...
(Date:4/27/2016)... Kan. , April 27, 2016  Bayer ... , a senior from the University of Florida ... of the Bayer Excellence in Communication Award (BECA). ... schools, which were awarded a total of $70,000 ... the last four years, Bayer has provided a ...
(Date:4/27/2016)... April 27, 2016 Global  ... 2.14 billion by 2022, according to a new ...      (Logo: http://photos.prnewswire.com/prnh/20150105/723757 ) , ... the efficiency and accuracy delivered by the new ... for novel urinalysis instruments and consumables. For instance, ...
Breaking Medicine Technology:
(Date:4/29/2016)... ... April 29, 2016 , ... ... of our nation’s productivity, stability, even security. Most importantly, employees are the single ... Then why are American workers so unhappy? , Just under half of American ...
(Date:4/29/2016)... STAMFORD, CONNECTICUT (PRWEB) , ... April 29, 2016 , ... ... 5K Run/Walk” at Cove Island Park on Sunday, with sunny skies, a light breeze ... event, raising nearly $33,000. , The 5k Run and Walk and 1-mile ...
(Date:4/29/2016)... ... April 29, 2016 , ... Spine Team Texas, a comprehensive spine ... announce one of their physicians has been invited to be a featured speaker at ... Practice Review conference on April 30, 2016. , Dr. R. Scott McPherson, a ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... announces the Gyrociser, an exercise invention which aids in proper muscle development. , ... Cooper, CEO and Creative Director of World Patent Marketing. "Globalization has threatened the ...
(Date:4/29/2016)... Torrance, CA (PRWEB) , ... April 29, 2016 , ... ... comprehensive cosmetic dental treatments to improve smiles. Cosmetic dentistry is a fast-growing field as ... smiles. This offer allows patients to learn more about the options currently available to ...
Breaking Medicine News(10 mins):